Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.

@article{Catanzaro2007PhaseIC,
  title={Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.},
  author={Andrew T. Catanzaro and Mario Roederer and Richard A. Koup and Robert T. Bailer and Mary E. Enama and Martha C. Nason and Julie E. Martin and Steve Rucker and Charla A. Andrews and Phillip L Gomez and John R. Mascola and Gary J. Nabel and Barney S. Graham},
  journal={Vaccine},
  year={2007},
  volume={25 20},
  pages={4085-92}
}
Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4(+) [13/14 (93%)] and CD8(+) [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and… CONTINUE READING